BIRC5 and cancer: In contrast, tumour suppressor p53 may counteract Sp1 binding to the promoter region and thereby reduce survivin expression.14, 15 As p53 is an essential and negative regulator of survivin, pharmacological approaches targeting p53‐survivin signalling might be a promising therapeutic strategy for intervention of cancer.